Bulging order book for bioconjugates lifts WuXi XDC profits
药明合联经调整纯利首破10亿元，产能出海迈入新周期

The provider of outsourced pharmaceutical services has delivered unexpectedly strong half-year earnings and has launched its first overseas production hub
2026年上半年实现营业收入37.01亿元，若按固定汇率（CER）剔除汇率波动影响后同比增幅达到41.5%，远超行业平均增速。